ClinicalTrials.gg
TerminatedNCT04100681FlowOxUpdated Aug 25, 2020

Intermittent Negative Pressure; Impact on Peripheral Artery Disease and Intermittent Claudication

An interventional study of Active FlowOx™ and Sham FlowOx™ (Placebo) in Peripheral Vascular Disease, Intermittent Claudication and Walking, Difficulty, sponsored by Otivio AS. Terminated at 5 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-25.

Sponsored by Otivio AS · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
The study was terminated early due to slow recruitment and inability to recruit patients during the Covid-19 situation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Peripheral Vascular Diseases with a site in Germany — 6 open to participants now, 8 under way, 1 of them phase 3. Peripheral Vascular Diseases · Germany.

Enrollment
48th of 50
16 · median 111
Started
2019
the only one that year
No phase
25 of 64
2 open now
Registered
48th of 64
by date

Among the 64 studies in Peripheral Vascular Diseases with a site in Germany, this one is the 48th largest by enrollment of the 50 interventional ones that give a count, is the only one that started in 2019, is one of 25 with no phase, and was the 48th registered.

Peripheral Vascular Diseases

443 studies on the registry are indexed under Peripheral Vascular Diseases; 44 are open to participants now.

Browse Peripheral Vascular Diseases studies →

Open to participants now

6 of the 64 studies in Peripheral Vascular Diseases with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 32 Peripheral Vascular Diseases studies recruiting now, 19 (59%) set no upper age limit and 4 (13%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Peripheral Vascular Diseases with a site in Germany, or all of them as a file.
02

Study summary

The objective is to ensure the pro-active collection of information on quality, safety and performance of FlowOx™ after it is placed on the market. The study will be carried out in a patient population with peripheral artery disease (claudicatio intermittens) to confirm its usefulness and in particular gather information for further improvements of the device related to this patient population. The data collected from the use of the CE-marked FlowOX™ device are change of walking distance, quality of life, and the patient's compliance.

Read the detailed description

A multi-center, randomized, sham (placebo)-controlled, double-blind trial to assess the efficacy and safety of FlowOx. This is done by comparing the increase in pain free walking distance compared to sham (placebo) device in patients with peripheral arterial disease (PAD) and intermittent claudication.

This study is conducted to assess the efficacy and safety of FlowOx™ compared to a sham FlowOx™ (placebo) device treatment. FlowOx™ can provide intermittent negative pressure (up to - 40 mmHg INP [intermittent negative pressure]) which is known to improve blood flow. The same device will also work as a sham (placebo) device by less negative pressure exerted by the device (in the range of -10 mmHg).

Daily home use of FlowOx™ for 2 hours (divided into minimum two sessions of 1 hour) per day in PAD-patients with intermittent claudication (stage II acc.to EMA, equivalent to Fontaine stage IIb in Germany) relative to sham (placebo) will be provided over a period of 12 weeks.

This efficacy study is evaluating the clinical effects of INP on patient with intermittent claudication with special focus on changes in pain free walking distance and quality of life.

03

Conditions studied

  • Peripheral Vascular Disease
  • Intermittent Claudication
  • Walking, Difficulty
  • Critical Limb Ischemia
  • Ischemia Limb
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female outpatients, age greater or equal 18 years
  • Stable evidence based pAVK therapy for at least 3 months
  • Ability to perform a treadmill test
  • Confirmation of clinical diagnosis of PAD as objective evidence of Fontaine stage IIb PAD i.e.:

    • Reduced ankle systolic blood pressure (ABI \<0.9) on target leg
    • Pain free walking distance \< 200 m in standardized walking test (initial claudication distance (ICD))
  • Completion of at least two treadmill tests within a time interval of greater or equal to 1 week prior to randomisation. Maximum change in claudication should not exceed a predefined threshold (\<25% for the absolute claudication distance (ACD)).
  • Intermittent claudication lasting for at least 3 months
  • Stable smoking habits for at least 3 months prior to inclusion
  • Signed

Exclusion criteria

Exclusion Criteria:

  • PAOD-patients with critical limb ischemia (CLI), equivalent to EMA's or Fontaine's PAOD-stages III and IV
  • Any kind of revascularization (endovascular, surgical) in the iliac or other leg arteries within 3 months prior to Visit 1
  • Patients with polyneuropathy
  • Other illnesses limiting exercise capacity (angina pectoris, heart failure, respiratory disease, orthopedic disease, neurological disorders)
  • Use of confounding medications within the last 4 weeks prior the Visit 1 e.g. vasoactive compounds like Cilostazol or Naftidrofuryl
  • Uncontrolled hypertension (> 180/95 mmHg) or hypotension (supine \< 100 mmHg)
  • Severe anemia
  • Pregnancy or lactation period
  • Woman with without an effective method (effective contraception method: hormonal contraceptive, hormonal vaginal devices or injections with prolonged release; an intrauterine device, or a barrier method of contraception such as condom or occlusive cap with spermicide (foam/gel/film/cream/suppository)
  • Planned surgical intervention requiring hospitalization during the clinical trial
  • Previous inclusion in the present clinical trial or parallel participation in other clinical trials (up to 8 weeks before Visit 1)
  • Incapability of understanding nature, meaning and consequences of the clinical trial
  • Patient unable to read and or write
  • Patients in custody by juridical or official order
  • Patients, who are members of the staff of the trial centre, staff of the sponsor or involved Clinical Research Organizations (CRO's), the investigator him-/herself or close relatives of the investigator
  • Patients unable to don or doff the FlowOx device (either themselves or with assistance from a helper).
  • Diagnosed acute deep vein thrombosis
  • Systemic infection
  • Alcohol disease or drug abuse
  • Malignant disease
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Active comparator
    Active FlowOx™

    The application of pulsating negative pressure will be up to 120 minutes long per day. The pulsating negative pressure used will be approximately 40 mm Hg alternating with ambient air pressure, the pulse consisting of 10 seconds of negative pressure followed by 7 seconds of atmospheric pressure.

    Device: Active FlowOx™

  • Sham comparator
    Sham FlowOx™ (Placebo)

    The application of a mild pulsating negative pressure will be up to 120 minutes long. The pulsating negative pressure used will be approximately 10 mm Hg alternating with ambient air pressure, the pulse consisting of 10 seconds of negative pressure followed by 7 seconds of atmospheric pressure.

    Device: Sham FlowOx™ (Placebo)

Interventions

  • DeviceActive FlowOx™

    Treatment is done by the patient at home for about 2 hours per day. Recommended to be 1 hour in the morning and 1 hour in the afternoon.

  • DeviceSham FlowOx™ (Placebo)

    Treatment is done by the patient at home for about 2 hours per day. Recommended to be 1 hour in the morning and 1 hour in the afternoon.

06

What researchers measure

Primary outcomes

  1. Change in pain-free walking distance from baseline to week 12

    The change will be calculated as difference in meters and compared between the interventional and the sham group.

    Time frame: baseline to week 12

Secondary outcomes

  1. Change in maximal walking distance from baseline to week 12

    The change will be calculated as difference in meters and compared between the interventional and the sham group.

    Time frame: 3 months treatment

  2. Change in Ankle Brachial index from baseline to week 12

    Determination of the ratio of the blood pressure at the ankle to the blood pressure in the upper arm (brachium)

    Time frame: from baseline to week 12

  3. Change in Quality of Life from baseline to week 12: EQ-5D-5L

    The 5-level EQ-5D (EuroQol- 5 Dimension) version (EQ-5D-5L) essentially consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). EQ-5D-5L describes the health condition of adults in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, extreme problems). Patient indicate their health states by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the 5 dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ-VAS score is read on a scale of 0-100 points (scale name: health condition), depending on where the patient has set his mark. 0 points mean the worst possible health condition, while 100 points is the best health possible.

    Time frame: from baseline to week 12

  4. Change in activity of daily living from baseline to week 12

    To evaluate the activity of daily living the standardized questionnaire VascuQoL-6 is used which comprises a set of 6 questions. Each question is scored 1-4. The sum of each individual question score is used to generate a "Total" Score. A higher value indicates better health status.

    Time frame: from baseline to week 12

  5. Determination of compliance of subjects as assessed by the time the device has been running

    The FlowOx device records the time the device has been running each time it was started. This record is saved on an USB stick which is readable by the study personnel only and serves to document the patient's compliance.

    Time frame: at week 12

07

Study locations

5 sites
  • Franziskus-Krankenhaus Berlin
    Berlin, 10787, Germany
  • Evangelisches Krankenhaus Hubertus, Gefäßzentrums Berlin-Brandenburg
    Berlin, 14129, Germany
  • Gemeinschaftspraxis
    Ettlingen, 76275, Germany
  • Universitätsmedizin Göttingen Georg-August-Universität
    Göttingen, 37075, Germany
  • Universitätsmedizin Johannes Gutenberg Universität
    Mainz, 55131, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Apr 2020, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2019
First posted
Sep 24, 2019
StartActual
Aug 19, 2019
Primary completionActual
Apr 1, 2020
CompletionActual
May 31, 2020
Last update
Aug 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04100681
Lead sponsor
Otivio AS
Collaborators
mediq Innovation Experts GmbH, Hannover Medical School
Responsible party
Sponsor
First posted
Sep 24, 2019
Start date
Aug 19, 2019
Primary completion
Apr 1, 2020
Completion
May 31, 2020
Last update
Aug 25, 2020

Study contacts

Holger Lawall, Dr. Med
principal investigator · Gemeinschaftspraxis
Silke Zimmermann, Dr. rer.nat.
study director · HCTC-KKS - Coordinating Center for Clinical Studies

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion